Rxcurve
HCPCS J0480 · per 20 MG

Basiliximab

Products billed under this code include Simulect.

Payment limit per 20 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.

Products billed under J0480

From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.

ProductLabelerNDCUnits / pkgLimit / pkg
Simulect Novartis Pharmaceuticals Corporation 00078-0331-84 1 $4,917.63
Simulect Novartis Pharmaceuticals Corporation 00078-0393-61 1 $4,917.63

Every quarter

QuarterPayment limitChangeBilling unitDescriptionSource file
4Q26 $4,917.63 +$12.581 20 MG Basiliximab v1, posted September 17, 2026
3Q26 $4,905.049 +$92.736 20 MG Basiliximab v1, posted September 15, 2026
2Q26 $4,812.313 +$31.24 20 MG Basiliximab v1, posted September 15, 2026
1Q26 $4,781.073 +$94.219 20 MG Basiliximab v1, posted September 15, 2026
4Q25 $4,686.854 +$14.387 20 MG Basiliximab v1, posted September 8, 2026
3Q25 $4,672.467 −$15.191 20 MG Basiliximab v1, posted March 10, 2026
2Q25 $4,687.658 +$30.077 20 MG Basiliximab v1, posted March 10, 2026
1Q25 $4,657.581 +$68.811 20 MG Basiliximab v1, posted December 19, 2025
4Q24 $4,588.77 +$7.547 20 MG Basiliximab v1, posted June 11, 2025
3Q24 $4,581.223 +$94.223 20 MG Basiliximab v1, posted June 11, 2025
2Q24 $4,487.00 +$10.735 20 MG Basiliximab v1, posted March 11, 2025
1Q24 $4,476.265 +$82.724 20 MG Basiliximab v1, posted December 19, 2024
4Q23 $4,393.541 +$4.459 20 MG Basiliximab v1, posted October 10, 2024
3Q23 $4,389.082 +$78.115 20 MG Basiliximab v1, posted June 5, 2024
2Q23 $4,310.967 +$72.279 20 MG Basiliximab v1, posted February 23, 2024
1Q23 $4,238.688 +$136.118 20 MG Basiliximab v1, posted December 6, 2023
4Q22 $4,102.57 +$14.902 20 MG Basiliximab v1, posted June 22, 2023
3Q22 $4,087.668 +$24.829 20 MG Basiliximab v1, posted June 9, 2023
2Q22 $4,062.839 +$25.188 20 MG Basiliximab v1, posted December 14, 2022
1Q22 $4,037.651 +$24.57 20 MG Basiliximab v1, posted June 8, 2022
4Q21 $4,013.081 −$16.146 20 MG Basiliximab v1, posted June 2, 2022
3Q21 $4,029.227 +$12.407 20 MG Basiliximab v1, posted June 2, 2022
2Q21 $4,016.82 −$2.25 20 MG Basiliximab v1, posted March 1, 2022
1Q21 $4,019.07 – 20 MG Basiliximab v1, posted December 10, 2021

“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.

CMS source files